In light of our previous results (13) and those from Baker et al. (12), showing FcRn dysregulation in lung and colorectal cancers and associated with an unfavorable outcome, our current findings further support the central role of FcRn in anti-tumor immunity and highlight the interest of targeting FcRn for therapeutic purposes. The gene discussed is FCGRT; the disease is neoplasm.